Houston, TX, August, 19, 2009 – TheraVasc, LLC was named one of the most promising Life Science companies at the 8th Annual Rice Alliance for Technology & Entrepreneurship Life Science Venture Forum in Houston last week. Life Science companies showcased their new ventures for an audience of more than 400 attendees, including investors, venture capitalists, […]

TheraVasc Inc., which is reformulating a drug to treat vascular diseases, has raised $1.8 million in its first round of investment capital. The funding comes from existing investors JumpStart Inc. and Portal Capital, and new investors North Coast Angel Fund, Ohio TechAngels and Dayton-based Physician Investment Group. In addition, more than a dozen individual investors […]

TheraVasc plans to begin enrolling patients this month in a phase 2a clinical trial of its pill designed to treat peripheral artery disease. The clinical trial, which is expected to follow 50 diabetic PAD patients for 11 weeks, could lead to big things for Cleveland-based TheraVasc. CEO Tony Giordano hopes a successful trial will position […]

Tony Giordano / President & CEO of TheraVasc – I am a molecular biologist with a Ph.D. from Ohio State University, and a serial entrepreneur, having started several venture-backed biotech companies in Pennsylvania. I founded TheraVasc two years ago in Cleveland, OH because I want to bring a promising new therapy from the lab to […]

A phase 1 trial of a peripheral artery disease drug candidate from TheraVasc demonstrated safety in diabetic patients. The positive clinical trial data reported by Cleveland-based TheraVasc potentially puts the young company one step closer to a development partnership with a big drug maker or a venture round between $10 million and $20 million. The […]

CLEVELAND, Sept. 20, 2011 /PRNewswire/ — TheraVasc (www.theravasc.com) announced the successful completion of a Phase I clinical trial of a drug, TV1001, to diabetic patients. The trial included 12 diabetic patients who each received a single dose of two different oral formulations of TV1001, an enteric coated and a non-enteric coated capsule, to determine safety […]

by Tristan Navera Dayton Business Journal – Febuary 4, 2015 Dr. Amol Soin is setting his sights on a new drug with immense potential for pain relief. It also has huge potential for helping to create the next billion-dollar company in the Dayton region. Soin, who is head of Centerville-based Ohio Pain Clinic, is part […]

Highland County Press Dr. Amol Soin, Medical Director of the Ohio Pain Clinic, with an office in Hillsboro, has announced the development of a treatment for diabetic neuropathy pain. Dr. Soin and his team filed a patent last February for an investigational, non-addicting/sedating pill and filed an Investigational New Drug Application with the FDA in […]

Watch the interview of Dr. Amol Soin on Fox 45 in Dayton as he explains our new experimental diabetic pain treatment.